Vericel Co. (NASDAQ:VCEL) Director Robert L. Md Zerbe Sells 3,278 Shares

Vericel Co. (NASDAQ:VCELGet Free Report) Director Robert L. Md Zerbe sold 3,278 shares of the company’s stock in a transaction that occurred on Wednesday, March 27th. The shares were sold at an average price of $51.57, for a total value of $169,046.46. Following the completion of the transaction, the director now directly owns 23,395 shares of the company’s stock, valued at approximately $1,206,480.15. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Vericel Stock Performance

Vericel stock opened at $52.02 on Friday. The stock has a market capitalization of $2.52 billion, a price-to-earnings ratio of -577.94 and a beta of 1.69. Vericel Co. has a 52-week low of $28.02 and a 52-week high of $52.50. The stock’s 50 day moving average price is $45.97 and its two-hundred day moving average price is $38.86.

Vericel (NASDAQ:VCELGet Free Report) last posted its quarterly earnings results on Thursday, February 29th. The biotechnology company reported $0.26 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.18 by $0.08. The firm had revenue of $65.00 million for the quarter, compared to analysts’ expectations of $64.28 million. Vericel had a negative return on equity of 1.55% and a negative net margin of 1.61%. The company’s revenue for the quarter was up 23.3% compared to the same quarter last year. During the same period in the prior year, the business earned $0.12 EPS. On average, equities research analysts forecast that Vericel Co. will post 0.09 EPS for the current year.

Hedge Funds Weigh In On Vericel

A number of institutional investors and hedge funds have recently modified their holdings of the business. Pinebridge Investments L.P. lifted its holdings in shares of Vericel by 718.0% in the 2nd quarter. Pinebridge Investments L.P. now owns 818 shares of the biotechnology company’s stock worth $31,000 after purchasing an additional 718 shares in the last quarter. DekaBank Deutsche Girozentrale bought a new position in shares of Vericel in the 4th quarter worth $33,000. Tower Research Capital LLC TRC lifted its holdings in shares of Vericel by 174.3% in the 1st quarter. Tower Research Capital LLC TRC now owns 1,668 shares of the biotechnology company’s stock worth $49,000 after purchasing an additional 1,060 shares in the last quarter. GAMMA Investing LLC bought a new position in shares of Vericel in the 4th quarter worth $65,000. Finally, Shell Asset Management Co. bought a new position in shares of Vericel in the 4th quarter worth $74,000.

Wall Street Analysts Forecast Growth

VCEL has been the topic of several analyst reports. TheStreet upgraded Vericel from a “d+” rating to a “c-” rating in a report on Monday, January 29th. HC Wainwright upped their target price on Vericel from $46.00 to $53.00 and gave the company a “buy” rating in a report on Friday, March 1st. Finally, Truist Financial reiterated a “buy” rating and issued a $54.00 target price on shares of Vericel in a report on Tuesday, March 26th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $46.40.

Check Out Our Latest Report on VCEL

About Vericel

(Get Free Report)

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.

Featured Stories

Insider Buying and Selling by Quarter for Vericel (NASDAQ:VCEL)

Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.